You are here: Industry Insights > CASI Pharmaceuticals

News List

BioInvent, CASI Pharmaceuticals Enter Antibody Alliance contractpharma
October 29, 2020
Collaboration accelerates and expands BioInvent's global development plans for BI-1206 in liquid and solid tumors.
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program prnewswire
June 09, 2020
CASI Pharmaceuticals, Inc. announced that it submitted a Clinical Trial Application (CTA) (IND) with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for CID-103.
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection firstwordpharma
December 04, 2018
CASI Pharmaceuticals Executive Chairman Wei-Wu He, Ph.D., commented, "NMPA approval of Melphalan Hydrochloride For Injection (EVOMELA®) is encouraging news for patients in China with multiple myeloma as there is no commercially available melphalan formula
CASI To Build GMP Mfg. Site In Wuxi, China contractpharma
November 19, 2018
CASI Pharmaceuticals has entered into agreements to build a state-of-the-art manufacturing site in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China. The Wuxi Huishan Economic Development Zone is a science and technology innovation cen
CASI Pharmaceuticals Acquires Laurus Lab's HBV Drug contractpharma
October 24, 2018
Expands pipeline and mission to commercialize U.S. FDA approved drugs in China
CASI Pharmaceuticals appoints new president for China Operations biospectrum
October 10, 2018
Zhang possesses over 20 years of executive experience in commercial operations, regulatory affairs, sales and marketing, and business development within the healthcare and biopharmaceutical industries in the U.S., Asia Pacificand China
CASI, Yiling Wanzhou team up to manufacture entecavir, cilostazol biospectrumasia
June 26, 2018
The contracted manufacturing facilities have been inspected by both the U.S. Food and Drug Administration (FDA) and China FDA (CFDA).
CASI Pharmaceuticals Reports on Enrollment Status of ENMD-2076 Phase 2 Study in Triple-Negative Brea americanpharmaceuticalreview
April 17, 2017
CASI Pharmaceuticals, Inc. has reported that a decision has been reached to stop further patient enrollment in its Phase 2, open-label study of ENMD-2076...